Janssen-Cilag Submits Marketing Authorisation Application in Europe for Paliperidone Palmitate for the Treatment of Schizophrenia
Beerse, Belgium, Janssen-Cilag International NV, has submitted a Marketing Authorisation Application to the European Medicines Agency for paliperidone palmitate, an investigational once-monthly atypical antipsychotic intramuscular injection for the treatment of schizophrenia.
Paliperidone palmitate utilises the NanoCrystal® Technology, which is a proprietary technology developed by Elan Drug Technologies through Elan Pharma International Limited and other Elan affiliates.
The paliperidone palmitate filing is based on an extensive global clinical development programme. Paliperidone palmitate was approved in the United States in July 2009. Marketing applications in other regions of the world are ongoing.
Upon approval, paliperidone palmitate will be marketed in Europe by the Janssen-Cilag companies, subsidiaries of Johnson & Johnson, the world’s most comprehensive manufacturer of health-care products and related services. More information about the company can be found at www.janssen-cilag.com.
An estimated one percent of the world’s population suffers from schizophrenia - a serious and usually chronic brain disorder that impairs a person’s ability to think clearly, relate to others and distinguish between reality and imagination. It typically develops in adolescence or the early 20s, although symptoms may not become immediately obvious and requires long-term or life-long treatment with antipsychotic drugs. More information can be found about schizophrenia at http://www.psychiatry24x7.com
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.